Isoliquiritigenin Suppresses EMT-Induced Metastasis in Triple-Negative Breast Cancer through miR-200c/C-JUN/ -Catenin

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Triple-negative breast cancer (TNBC) is aggressive and lacks effective treatments.
• Isoliquiritigenin (ISL) demonstrated prior anticancer effects on breast cancer.
• The specific mechanisms of ISL on TNBC require further elucidation.

Purpose of the Study:

• To investigate the effects of ISL on TNBC growth, metastasis, and underlying molecular mechanisms.
• To explore the role of miR-200c in ISL's anti-TNBC activity.
• To assess ISL as a potential therapeutic agent for TNBC.

Main Methods:

• PCR array and in situ hybridization (ISH) to analyze miR-200c expression.
• In vitro cell culture (BT-549 and MDA-MB-231 cells) to study epithelial-mesenchymal transition (EMT).
• In vivo studies using nude mice models to evaluate tumor growth and metastasis inhibition.
• Analysis of c-Jun expression and miR-200c promoter methylation.

Main Results:

• ISL treatment significantly increased miR-200c levels in TNBC cells.
• ISL suppressed epithelial-mesenchymal transition (EMT) and inhibited metastasis and tumor growth in vivo.
• ISL decreased c-Jun expression, potentially via miR-200c up-regulation.
• ISL may enhance miR-200c expression by demethylating its promoter region.

Conclusions:

• ISL effectively inhibits TNBC growth and metastasis, mediated by miR-200c up-regulation.
• ISL's mechanism involves suppressing EMT and reducing c-Jun expression.
• ISL shows potential as a novel therapeutic candidate for TNBC, particularly in microRNA-based strategies.